SLC29A1 and non-small cell lung carcinoma: Similar results were reported in non-small cell lung cancer cells (Giovannetti et al, 2005), suggesting that modulation of dCK and hENT1 gene expression as well as inhibition of Akt phosphorylation by pemetrexed may be involved in the improvement of gemcitabine therapeutic potential against several cell lines.